- Home
- BMRA vs CVKD Comparison
BMRA vs CVKD Comparison
Compare BMRA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- CVKD
- Stock Information
- Founded
- BMRA 1971
- CVKD 2022
- Country
- BMRA United States
- CVKD United States
- Employees
- BMRA N/A
- CVKD N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BMRA Health Care
- CVKD Health Care
- Exchange
- BMRA Nasdaq
- CVKD Nasdaq
- Market Cap
- BMRA 8.2M
- CVKD 29.5M
- IPO Year
- BMRA N/A
- CVKD 2023
- Fundamental
- Price
- BMRA $2.99
- CVKD $13.37
- Analyst Decision
- BMRA
- CVKD Strong Buy
- Analyst Count
- BMRA 0
- CVKD 1
- Target Price
- BMRA N/A
- CVKD $32.00
- AVG Volume (30 Days)
- BMRA 436.0K
- CVKD 25.3K
- Earning Date
- BMRA 10-14-2025
- CVKD 11-06-2025
- Dividend Yield
- BMRA N/A
- CVKD N/A
- EPS Growth
- BMRA N/A
- CVKD N/A
- EPS
- BMRA N/A
- CVKD N/A
- Revenue
- BMRA $5,311,000.00
- CVKD N/A
- Revenue This Year
- BMRA N/A
- CVKD N/A
- Revenue Next Year
- BMRA N/A
- CVKD N/A
- P/E Ratio
- BMRA N/A
- CVKD N/A
- Revenue Growth
- BMRA N/A
- CVKD N/A
- 52 Week Low
- BMRA $2.08
- CVKD $8.74
- 52 Week High
- BMRA $10.16
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BMRA 46.09
- CVKD 55.51
- Support Level
- BMRA $2.74
- CVKD $13.00
- Resistance Level
- BMRA $3.08
- CVKD $13.72
- Average True Range (ATR)
- BMRA 0.22
- CVKD 0.61
- MACD
- BMRA 0.00
- CVKD -0.00
- Stochastic Oscillator
- BMRA 51.69
- CVKD 60.27
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.